Date: 2013-11-20
Type of information: Fundraising
Company: Pulmocide (UK)
Investors: Imperial Innovations Group (UK), SV Life Sciences (UK - USA), Fidelity Biosciences (USA), Johnson & Johnson Development Corporation (JJDC) (USA)
Amount: £17million (€20.4 million)
Funding type: financing round
Planned used:
Others: * On November 20, 2013, Imperial Innovations Group, a UK technology commercialisation and investment group, has completed an investment in Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. Imperial Innovations is investing £4.25m as part of a consortium of leading venture investors which includesSV Life Sciences, Fidelity Biosciences and Johnson & Johnson Development Corporation (JJDC). Pulmocide will be based at the Imperial BioIncubator in London. The Pulmocide management team, led by Garth Rapeport (CEO) and Pete Strong (CSO), were previously co-founders of Respivert Ltd which was acquired by Janssen Biotech Inc in 2010. In addition, they facilitated the spin-out of Topivert Ltd from Respivert. Topivert is developing topical anti-inflammatories for the treatment of diseases of the gastrointestinal tract and eye.
Therapeutic area: Infectious diseases -Respiratory diseases
